Regenerative Medicine Centers Explained: The 2026 Patient’s Guide to Types, FDA Rules & Vetting

Introduction: Why “Regenerative Medicine Center” Means Four Different Things

A patient who searches for “regenerative medicine centers” usually expects to find one kind of facility. The results cover much more ground. The same label is used by a world-class academic hospital program and by a strip-mall med-spa offering exosome facials. Both may say they practice regenerative medicine, yet their oversight, evidence standards, and accountability are very different.

The sector is large and growing fast. Analysts project the global regenerative medicine market at roughly $48 to $58 billion in 2026, with double-digit annual growth expected into the early 2030s. North America holds the largest share, estimated at between 39% and 58.6% depending on the methodology. Many of these treatments sit in regulatory gray zones, and market growth does not mean they are FDA-approved or covered by insurance. That gap is the reason vetting matters.

This guide maps the four main types of centers against the FDA’s regulatory framework. It covers the 351 vs. 361 product distinction, the “same surgical procedure” exception, and enforcement trends from 2025 and 2026, then turns that material into a plain-language vetting checklist. Law-firm briefings tend to be written for industry, and red-flag listicles rarely explain the regulations behind their warnings. This guide is written for patients. It is also a hub for TopDoctor Magazine’s deeper coverage of peptides, stem cells, and local provider searches.

What Is a Regenerative Medicine Center? A Category, Not a Clinic Type

Regenerative medicine covers treatments intended to repair, replace, or regenerate tissue. These treatments use either the body’s own biological material or cell and tissue products processed in a lab. Common modalities include:

• PRP (platelet-rich plasma)
• BMAC (bone marrow aspirate concentrate)
• Adipose-derived (fat-derived) cell therapy
• Exosome therapy
• Prolotherapy
• Peptide therapy

Patients should understand one point early: a center offering these treatments does not mean the treatments are FDA-approved for the condition being treated. The list of FDA-approved cell-based therapies is still short. It includes hematopoietic stem cell transplants for blood cancers and blood disorders, plus a small but growing group of approved cell and gene therapies, such as Ryoncil, a mesenchymal stromal cell therapy approved in 2024. Most orthopedic, anti-aging, and cosmetic stem cell or exosome offerings at private centers are not FDA-approved.

“Regenerative medicine center” is not a licensed or standardized term. As a result, four very different business models operate under the same label.

The Four Types of Regenerative Medicine Centers, Mapped

The four types differ in institutional backing, regulatory oversight, typical treatments, and cost transparency.

Academic Medical Center Programs

Institutions such as Mayo Clinic’s Center for Regenerative Medicine and Cleveland Clinic’s National Center for Regenerative Medicine run structured programs with a formal consult service and multispecialty knowledge board. These typically include:

• A formal consult service
• A multispecialty knowledge board
• Dedicated research pipelines

These programs usually offer investigational (351-track) therapies through IRB-approved clinical trials rather than off-label cash-pay products. They carry the highest institutional accountability. The trade-off is a narrower treatment menu, strict eligibility criteria, and longer waits.

Hospital-Affiliated Regenerative Centers

These are departments or satellite clinics that operate under a hospital system’s license and compliance infrastructure. They often focus on orthopedics and sports medicine, offering PRP and BMAC alongside physical therapy and surgical referral pathways. Hospital credentialing, malpractice coverage, and institutional review generally make them more accountable than independent clinics. Even so, most treatments are still paid out-of-pocket.

Independent / Boutique Regenerative Clinics

These physician-owned practices, operating from a single location or several, specialize in orthopedic, anti-aging, or integrative regenerative care. Quality varies more here than in any other category. Some are run by board-certified specialists who follow rigorous protocols. Others market unapproved stromal vascular fraction (SVF) and exosome products.

This segment has drawn the most FDA warning letters and untitled letters in 2024 through 2026, including actions against firms such as Evolutionary Biologics, Chara Biologics, Supreme Rejuvenation, and Innate Healthcare Institute. It needs the most careful vetting.

Med-Spa / Wellness Franchise Centers

These multi-service businesses have added “regenerative” treatments, such as PRP facials, exosome hair restoration, and peptide therapy, to their aesthetics and IV therapy menus. Treatments are often delivered by nurse practitioners or aestheticians. Physician oversight may be minimal or remote, and in some cases the medical director is little more than a name on paper. Marketing often blurs cosmetic and medical claims, and franchise models can weaken quality control from one location to the next. This category also shows the most overlap with a major red flag: one product marketed to treat unrelated conditions, from joint pain to sexual enhancement.

Comparison Snapshot: Choosing the Right Category for Your Needs

Center type alone does not guarantee safety. A boutique clinic can be excellent, and a franchise location can be careless. The criteria below apply to all four types.

The FDA Framework Every Patient Should Understand Before Booking

Most regenerative products are not regulated as conventional drugs. They fall under a separate category called Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps), which the FDA oversees through a two-track system.

351 vs. 361 Products: The Core Distinction

• 361 products are considered low-risk. They are minimally manipulated and intended for homologous use, meaning they perform the same basic function in the body that the original tissue did. They do not need premarket FDA approval.
• 351 products are more than minimally processed or are used for a non-homologous purpose. They are regulated as biologics and require an IND (investigational new drug application) or BLA (biologics license application) before they can be marketed.

The technical basis is the FDA’s Minimal Manipulation and Homologous Use guidance, which draws on definitions in 21 CFR 1271.3(f). In plain language, the question is: Does the treatment use the patient’s own tissue in a way that matches its natural function, with minimal lab processing?

Same-day PRP or bone marrow injections for joint pain often qualify as 361 products. Enzymatically processed SVF and expanded or cultured stem cells usually do not.

The “Same Surgical Procedure” Exception, and Why It’s Often Misused

Under 21 CFR 1271.15(b), tissue that is removed from a patient and put back into that same patient during the same procedure, without more-than-minimal processing, is exempt from FDA premarket requirements. The exception is narrow and procedure-specific. It does not cover every treatment simply because it is “autologous,” or made from the patient’s own tissue.

The FDA’s 2024 warning letter to Mother Stem Institute Corp shows how the agency reads this rule. When enzymatic digestion breaks down the original structure of fat tissue, the FDA’s position is that the clinic has turned that tissue into a different product: an injectable drug. The agency said the adipose tissue removed from patients “is different from” the SVF product later given to them. In September 2024, the Ninth Circuit reinforced this reasoning in U.S. v. California Stem Cell Treatment Center, affirming FDA authority over SVF treatments marketed under the exception.

Patient takeaway: A claim that a treatment is “legal because it’s your own cells” does not, on its own, show that the treatment complies with federal rules.

2025-2026 Enforcement and Policy Trends Patients Should Know

HHS Secretary Robert F. Kennedy Jr., who was confirmed in February 2025, has spoken favorably about deregulation. Even so, STAT News reported in September 2026 that FDA’s Center for Biologics Evaluation and Research (CBER) continues to issue warning letters, particularly to perinatal and exosome product suppliers and to stem cell clinics.

In September 2025, the FDA also released draft guidance describing expedited review pathways for regenerative medicine therapies. This change affects future approved products. It does not make unapproved treatments now offered in clinics legal. Enforcement in 2026 is active and still changing, so patients should check a center’s current standing instead of assuming a treatment is fine because the clinic has not been cited yet.

Accreditation Standards: The Vetting Signal Most Patients Never Check

Two independent organizations set quality benchmarks for cellular therapy:

• AABB (Association for the Advancement of Blood & Biotherapies)
• FACT (Foundation for the Accreditation of Cellular Therapy)

AABB has “deemed status” from CMS, and some insurers require AABB accreditation before they will reimburse certain procedures. That makes it a strong indicator of legitimacy. Discussion of these accreditations is almost entirely limited to cord-blood banking content, so few patients think to ask about them when choosing a regenerative center.

Action step: Ask whether the facility or its lab processing partner holds AABB or FACT accreditation. Then confirm the answer in each organization’s public directory.

What Can Go Wrong: Documented Risks and Enforcement Cases

In 2017, the New England Journal of Medicine published a case series describing three patients who suffered severe, permanent vision loss, including complete blindness, after receiving unproven injections of autologous fat-derived “stem cells” into both eyes for macular degeneration at a U.S. clinic.

The problem is not limited to the past. The wave of warning letters to exosome and stem cell firms from 2024 through 2026 shows that risky products are still on the market. The Ninth Circuit’s ruling in the California Stem Cell Treatment Center case confirmed that the FDA can regulate unapproved SVF treatments as drugs, which closed off a legal argument many clinics had relied on.

Harm and enforcement actions tend to cluster in the same places: independent clinics and franchises offering non-homologous, more-than-minimally manipulated products without accreditation or trial oversight.

The Cost and Insurance Reality

• PRP injections: $500 to $2,500 per session
• Stem cell protocols: $3,000 to $12,000+ per treatment

Most patients pay these costs out-of-pocket. Medicare, Medicaid, and major commercial insurers such as Aetna, Cigna, and UnitedHealthcare classify these procedures as experimental or investigational for orthopedic and most non-oncology uses.

A high price or polished marketing says nothing about FDA compliance or the strength of the clinical evidence. Patients should ask for an itemized, written cost breakdown and find out whether the treatment is billed as a covered medical service or as a self-pay elective procedure.

The Patient Vetting Framework: 8 Questions to Ask Before You Book

These questions combine FDA classification, accreditation status, and known red flags into one checklist that works at any type of center.

1. What Exactly Is the Product, and Is It 351 or 361?

Ask whether the product is minimally manipulated and used for its natural (homologous) purpose. Find out how it is processed: same-day or sent to an outside lab, and simple centrifugation or enzymatic digestion.

2. Is the Same Surgical Procedure Exception Being Invoked Correctly?

Confirm that the tissue is removed and re-implanted during the same procedure without more-than-minimal processing. Be skeptical if the clinic’s only legal justification is “it’s your own cells.”

3. Does the Facility or Lab Hold AABB or FACT Accreditation?

Ask for credentials and check them independently. Treat a lack of accreditation as a caution flag, especially for more heavily processed products.

4. Has the Clinic or Its Product Received FDA Warning Letters?

The FDA’s warning letter and untitled letter databases are public and free to search. Clinics or suppliers named in 2024 through 2026 enforcement actions should be treated as high-risk.

5. Is the Treatment Being Marketed for Too Many Unrelated Conditions?

A single injection advertised for orthopedic, neurological, cardiac, cosmetic, and sexual-enhancement problems is a major warning sign. Evidence-based regenerative treatments target specific conditions that have been studied.

6. Who Is Actually Performing and Overseeing the Procedure?

Check the treating provider’s credentials and ask what the medical director actually does day to day. Look for board certification that matches the condition being treated, such as orthopedics for joint injections.

7. Is There Clinical Evidence, or Just Testimonials?

Ask for peer-reviewed studies or clinical trial data on the specific product and condition. Before-and-after testimonials are not evidence. Academic programs connect their treatments to research pipelines and IRB oversight; many independent clinics do not.

8. What Does Informed Consent Disclose About Risk and Approval Status?

Written consent forms should state clearly when a product is not FDA-approved and should list its known risks. The NEJM blindness cases show why complete risk disclosure matters.

Putting It Together: A Quick-Reference Vetting Checklist by Center Type

Academic programs meet most of these criteria by design. Hospital-affiliated centers usually meet most of them as well. Independent clinics and franchise centers deserve the closest scrutiny on every question.

Printable checklist:

• ☐ Product classification (351/361) explained clearly
• ☐ Processing method disclosed
• ☐ Same surgical procedure claim holds up
• ☐ AABB/FACT accreditation verified
• ☐ No FDA warning or untitled letters found
• ☐ Narrow, specific list of treated conditions
• ☐ Board-certified provider in the relevant specialty
• ☐ Peer-reviewed evidence provided
• ☐ Written informed consent that states approval status

No single factor, whether price, marketing polish, or physician credentials, can replace checking FDA classification and accreditation status.

Conclusion: Making an Informed Choice in a Fast-Growing, Unevenly Regulated Field

“Regenerative medicine center” can describe anything from an academic hospital program to a med-spa. Whether a treatment is legitimate depends on its FDA classification, on proper use of the same surgical procedure exception, and on accreditation. Marketing and price do not answer those questions.

The field holds real promise. The market is growing, the list of FDA-approved therapies is expanding, and new expedited review pathways may bring approved treatments to patients faster. Patient vigilance remains essential in 2026. This guide is a starting point; the next step is to apply the framework to specific treatments and specific local providers.

Next Steps: Continue Your Research with TopDoctor Magazine

TopDoctor Magazine covers regenerative, functional, integrative, and personalized medicine. Readers can explore its deeper guides on peptide therapy, stem cell treatments, and finding vetted regenerative providers nearby. The magazine’s nomination platform highlights physicians nominated by patients and peers for meaningful contributions to their profession and their patients.

To follow FDA regulatory updates and provider features, readers can subscribe to the free TopDoctor biweekly newsletter.

Healthcare professionals who run accredited, compliant regenerative medicine centers are invited to contact TopDoctor Magazine at info@topdoctormagazine.com about editorial features or award nominations.